

**TO: Rachel Adams**

**From : Chih-Min Kam**  
**Patent Examiner**  
**Tel: (571) 272-0948**

**Total Pages: 4**

**Fax No: (202) 942-5999**

**Messages: Proposed Examiner's Amendment for 09/834,008**  
**(Attorney Docket No< 16991.008)**

**Proposed Examiner's Amendments to the Claims:**

Claims 19, 20, 25, 33, 35, 43, 49, 52 and 53 have been amended as follows:

19. (Currently amended) The method of claim 13, wherein the weight ratio of human OCIF protein to polysaccharide is at least about 1:4; OCIF : polysaccharide.

20. (Currently Amended) A method of treating a bone-pathobolism selected from the group consisting of: osteoporosis, hypercalcemia and chronic articular rheumatism comprising administering to a subject in need thereof a composition comprising an amount of human osteoclastogenesis inhibitory factor (OCIF) protein and a polysaccharide, effective in combination for increasing bone density; wherein the polysaccharide is selected from the group consisting of: hyaluronic acid, chondroitin sulfate, dermatan sulfate, heparan sulfate, keratan sulfate, carrageenan, pectin, heparin, dextran, dextran sulfate, and sulfated glucan; thereby increasing the subjects bone density.

25. (Currently amended) The method of claim 20, wherein the weight ratio of human OCIF protein to polysaccharide in said composition is at least about 1:4; OCIF : polysaccharide.

33. (Currently Amended) A medicinal composition for treating a bone-pathobolism selected from the group consisting of: osteoporosis, hypercalcemia and chronic articular rheumatism, said composition comprising: a human osteoclastogenesis inhibitory factor (OCIF) protein homolog selected from the group consisting of human OCIF2, human OCIF3, human OCIF4, and human OCIF5; and a polysaccharide selected from the group consisting of: hyaluronic acid, chondroitin sulfate, dermatan sulfate, heparan sulfate, keratan sulfate, carrageenan, pectin, heparin, dextran, dextran sulfate, and sulfated glucan.

Art Unit: 1653

35. (Currently Amended) A method of treating a bone-pathobolism selected from the group consisting of: osteoporosis, hypercalcemia and chronic articular rheumatism comprising administering to a subject in need thereof a composition comprising an amount of a human osteoclastogenesis inhibitory factor (OCIF) protein homolog and a polysaccharide, effective in combination for increasing bone density; wherein said OCIF protein homolog is selected from the group consisting of: human OCIF2, human OCIF3, human OCIF4, and human OCIF5; and wherein said polysaccharide is selected from the group consisting of: hyaluronic acid, chondroitin sulfate, dermatan sulfate, heparan sulfate, keratan sulfate, carrageenan, pectin, heparin, dextran, dextran sulfate, and sulfated glucan; thereby increasing the subjects bone density.

43. (Currently amended) The method of claim 40, wherein the weight ratio of human OCIF protein to polysaccharide is at least about 1:4; OCIF : polysaccharide.

49. (Currently amended) The method of claim 46, wherein the weight ratio of human OCIF protein to polysaccharide is at least about 1:4; OCIF : polysaccharide.

52. (Currently Amended) A lyophilized medicinal composition for treating a bone-pathobolism selected from the group consisting of: osteoporosis, hypercalcemia and chronic articular rheumatism, said composition comprising: a human osteoclastogenesis inhibitory factor (OCIF) protein homolog selected from the group consisting of human OCIF2, human OCIF3, human OCIF4, and human OCIF5, and a polysaccharide selected from the group consisting of: hyaluronic acid, chondroitin sulfate, dermatan sulfate, heparan sulfate, keratan sulfate, carrageenan, pectin, heparin, dextran, dextran sulfate, and sulfated glucan.

53. (Currently Amended) A method of preparing a lyophilized medicinal composition for treating a bone-pathobolism selected from the group consisting of: osteoporosis, hypercalcemia and chronic articular rheumatism, said composition comprising a human osteoclastogenesis inhibitory factor (OCIF) protein homolog selected from the group

Art Unit: 1653

consisting of human OCIF2, human OCIF3, human OCIF4, and human OCIF5, and a polysaccharide selected from the group consisting of: hyaluronic acid, chondroitin sulfate, dermatan sulfate, heparan sulfate, keratan sulfate, carrageenan, pectin, heparin, dextran, dextran sulfate, and sulfated glucan, said method comprising:

- dissolving OCIF homolog and said polysaccharide in a solution; and
- freeze-drying the solution comprising said OCIF homolog and said polysaccharide.